The platform analyzes infrared spectroscopy data from a small sample of blood with proprietary algorithms to detect cancer early.

The award supports development of a portable test system using the firm's protein nucleic acid probes and semiconductor sensor tech.

The new funding will help the cluster build on initial milestones and to prepare for clinical applications, particularly in cancer.

Last week, readers were most interested in a story about the conviction of lab owner, formerly an NFL player, for genetic testing fraud.

Life Line aims to offer Lucent's blood-based testing through its mobile delivery model at urban and rural community health screening events.

Among the major issues were tariff policies, reimbursement pathways for multi-cancer early detection tests, and reform of the ...

Moffit Cancer Center researchers found four "protein EpiScores" that were associated with disease-free survival, one of which was also associated with overall survival.

NEW YORK – Irish diagnostic firm Trinity Biotech announced on Wednesday that it has entered into a $25 million standby equity purchase agreement with an affiliate of its financing partner Yorkville ...

Natera expects additional reimbursement coverage for its oncology tests in 2026 that may drive increases in average selling prices and volumes, company executives said on Thursday. Separately this ...

NEW YORK — BioAffinity Technologies said on Wednesday that it will run a study of its CyPath Lung test for early lung cancer detection in collaboration with Brooke Army Medical Center (BAMC). CyPath ...

The interferon-gamma release assay for latent tuberculosis infection is designed for use on Diasorin's automated, high-throughput Liaison XL platform.